184 related articles for article (PubMed ID: 7970453)
1. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486.
Chan AF; Mortola JF; Wood SH; Yen SS
Obstet Gynecol; 1994 Dec; 84(6):1001-5. PubMed ID: 7970453
[TBL] [Abstract][Full Text] [Related]
2. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study.
Wood SH; Mortola JF; Chan YF; Moossazadeh F; Yen SS
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):339-44. PubMed ID: 1495689
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of induced menses on symptoms in women with premenstrual syndrome.
Schmidt PJ; Nieman LK; Grover GN; Muller KL; Merriam GR; Rubinow DR
N Engl J Med; 1991 Apr; 324(17):1174-9. PubMed ID: 2011161
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.
Brown CS; Ling FW; Andersen RN; Farmer RG; Arheart KL
Obstet Gynecol; 1994 Nov; 84(5):779-86. PubMed ID: 7936512
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
Freeman EW; Sondheimer SJ; Rickels K
Psychopharmacol Bull; 1997; 33(2):303-9. PubMed ID: 9230648
[TBL] [Abstract][Full Text] [Related]
6. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.
Sundström I; Nyberg S; Bixo M; Hammarbäck S; Bäckström T
Acta Obstet Gynecol Scand; 1999 Nov; 78(10):891-9. PubMed ID: 10577620
[TBL] [Abstract][Full Text] [Related]
7. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences.
Mortola JF; Girton L; Beck L; Yen SS
Obstet Gynecol; 1990 Aug; 76(2):302-7. PubMed ID: 2371035
[TBL] [Abstract][Full Text] [Related]
9. Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome.
Nyberg S; Bäckström T; Zingmark E; Purdy RH; Poromaa IS
Gynecol Endocrinol; 2007 May; 23(5):257-66. PubMed ID: 17558683
[TBL] [Abstract][Full Text] [Related]
10. Progesterone metabolite allopregnanolone in women with premenstrual syndrome.
Rapkin AJ; Morgan M; Goldman L; Brann DW; Simone D; Mahesh VB
Obstet Gynecol; 1997 Nov; 90(5):709-14. PubMed ID: 9351749
[TBL] [Abstract][Full Text] [Related]
11. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study.
Wang M; Hammarbäck S; Lindhe BA; Bäckström T
Acta Obstet Gynecol Scand; 1995 Nov; 74(10):803-8. PubMed ID: 8533564
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study.
Freeman EW; Sondheimer SJ; Rickels K; Albert J
J Clin Psychiatry; 1993 May; 54(5):192-5. PubMed ID: 8509350
[TBL] [Abstract][Full Text] [Related]
13. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.
Schmidt PJ; Nieman LK; Danaceau MA; Adams LF; Rubinow DR
N Engl J Med; 1998 Jan; 338(4):209-16. PubMed ID: 9435325
[TBL] [Abstract][Full Text] [Related]
14. Mood and cognitive style in premenstrual syndrome.
Rapkin AJ; Chang LC; Reading AE
Obstet Gynecol; 1989 Oct; 74(4):644-9. PubMed ID: 2797641
[TBL] [Abstract][Full Text] [Related]
15. Decreased central opioid activity in premenstrual syndrome: luteinizing hormone response to naloxone.
Rapkin AJ; Shoupe D; Reading A; Daneshgar KK; Goldman L; Bohn Y; Brann DW; Mahesh VB
J Soc Gynecol Investig; 1996; 3(2):93-8. PubMed ID: 8796815
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
[TBL] [Abstract][Full Text] [Related]
17. [The role of the progesterone antagonist, RU 486 (mifepristone), in preoperative cervical dilatation during the luteal phase. A randomized double-blind study].
Fernandez H; Durlot F; Dubois C; Ulmann A; Frydman R
Contracept Fertil Sex (Paris); 1990 Jan; 18(1):41-3. PubMed ID: 12283016
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.
Canning S; Waterman M; Orsi N; Ayres J; Simpson N; Dye L
CNS Drugs; 2010 Mar; 24(3):207-25. PubMed ID: 20155996
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome.
London RS; Murphy L; Kitlowski KE; Reynolds MA
J Reprod Med; 1987 Jun; 32(6):400-4. PubMed ID: 3302248
[TBL] [Abstract][Full Text] [Related]
20. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study.
Berger CP; Presser B
Obstet Gynecol; 1994 Sep; 84(3):379-85. PubMed ID: 8058235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
